U.S. flag

An official website of the United States government

NM_058216.3(RAD51C):c.93del (p.Phe32fs) AND not specified

Germline classification:
Pathogenic (1 submission)
Last evaluated:
Apr 7, 2019
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001001178.8

Allele description [Variation Report for NM_058216.3(RAD51C):c.93del (p.Phe32fs)]

NM_058216.3(RAD51C):c.93del (p.Phe32fs)

Gene:
RAD51C:RAD51 paralog C [Gene - OMIM - HGNC]
Variant type:
Deletion
Cytogenetic location:
17q22
Genomic location:
Preferred name:
NM_058216.3(RAD51C):c.93del (p.Phe32fs)
HGVS:
  • NC_000017.11:g.58692736del
  • NG_023199.1:g.5135del
  • NG_047169.1:g.4347del
  • NM_002876.4:c.93del
  • NM_058216.3:c.93delMANE SELECT
  • NP_002867.1:p.Phe32fs
  • NP_478123.1:p.Phe32fs
  • LRG_314t1:c.93del
  • LRG_314:g.5135del
  • NC_000017.10:g.56770094del
  • NC_000017.10:g.56770097del
  • NC_000017.10:g.56770097delG
  • NM_002876.2:c.93delG
  • NM_058216.1:c.93del
  • NM_058216.1:c.93delG
  • NM_058216.2:c.93delG
  • NR_103872.2:n.135del
  • p.F32SfsX8
  • p.G31GFS*9
Protein change:
F32fs
Links:
OMIM: 602774.0007; dbSNP: rs730881942
NCBI 1000 Genomes Browser:
rs730881942
Molecular consequence:
  • NM_002876.4:c.93del - frameshift variant - [Sequence Ontology: SO:0001589]
  • NM_058216.3:c.93del - frameshift variant - [Sequence Ontology: SO:0001589]
  • NR_103872.2:n.135del - non-coding transcript variant - [Sequence Ontology: SO:0001619]

Condition(s)

Synonyms:
AllHighlyPenetrant
Identifiers:
MedGen: CN169374

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001158330ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
criteria provided, single submitter

(ARUP Molecular Germline Variant Investigation Process)
Pathogenic
(Apr 7, 2019)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Details of each submission

From ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories, SCV001158330.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testingnot provided

Description

The RAD51C c.93delG; p.Phe32fs variant (rs730881942) is reported in the literature in individuals with breast and/or ovarian cancer, prostate cancer, soft tissue sarcoma, or hematologic cancer (Pelttari 2011, Pritchard 2016, Schrader 2016, Susswein 2016). This variant is reported as pathogenic by multiple laboratories in ClinVar (Variation ID: 182847). It is found in the general population with an overall allele frequency of 0.005% (13/282860 alleles) in the Genome Aggregation Database. This variant causes a frameshift by deleting a single nucleotide, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. REFERENCES Pelttari LM et al. RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet. 2011 Aug 15;20(16):3278-88. Pritchard CC et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med. 2016 Aug 4;375(5):443-53. Schrader KA et al. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncol. 2016 Jan;2(1):104-11. Susswein LR et al. Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing. Genet Med. 2016 Aug;18(8):823-32.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024